Oculis Holding AG (NASDAQ:OCS) Short Interest Update

Oculis Holding AG (NASDAQ:OCS - Get Free Report) was the recipient of a large growth in short interest in the month of May. As of May 31st, there was short interest totalling 21,700 shares, a growth of 29.9% from the May 15th total of 16,700 shares. Based on an average daily volume of 37,400 shares, the short-interest ratio is currently 0.6 days. Currently, 0.1% of the company's shares are sold short.

Oculis Price Performance

Shares of Oculis stock traded down $0.20 during trading on Friday, reaching $19.28. 45,000 shares of the company traded hands, compared to its average volume of 45,243. The firm has a market capitalization of $841.76 million, a PE ratio of -7.30 and a beta of 0.35. Oculis has a 1-year low of $10.79 and a 1-year high of $23.08. The company has a 50 day moving average price of $18.55 and a 200-day moving average price of $18.97.

Oculis (NASDAQ:OCS - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.26). Oculis had a negative net margin of 13,788.70% and a negative return on equity of 92.95%. The company had revenue of $0.32 million for the quarter, compared to analyst estimates of $0.22 million. Equities research analysts expect that Oculis will post -2.09 earnings per share for the current year.

Institutional Investors Weigh In On Oculis

A number of hedge funds have recently added to or reduced their stakes in the company. Bellevue Group AG bought a new position in shares of Oculis in the 4th quarter worth $170,000. XTX Topco Ltd acquired a new position in Oculis during the fourth quarter worth $225,000. Kestra Private Wealth Services LLC bought a new position in shares of Oculis in the first quarter valued at $234,000. Geode Capital Management LLC lifted its stake in shares of Oculis by 12.0% in the fourth quarter. Geode Capital Management LLC now owns 16,744 shares of the company's stock valued at $284,000 after buying an additional 1,800 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new position in shares of Oculis during the fourth quarter valued at about $389,000. Institutional investors and hedge funds own 22.30% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on OCS shares. Chardan Capital lifted their target price on shares of Oculis from $28.00 to $33.00 and gave the stock a "buy" rating in a research note on Friday, May 9th. HC Wainwright lifted their price objective on Oculis from $29.00 to $32.00 and gave the stock a "buy" rating in a research report on Thursday, April 17th. Finally, Robert W. Baird upped their target price on Oculis from $37.00 to $41.00 and gave the company an "outperform" rating in a research report on Thursday, March 13th.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.